Form 4: Iovance Biotherapeutics Chief Medical Officer Friedrich Graf Finckenstein Reports Stock Transactions
SEC Form 4
Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.
Summary
- On March 4, 2024, Friedrich Graf Finckenstein, the Chief Medical Officer of Iovance Biotherapeutics, had 15,623 restricted stock units (RSUs) vest.
- The company withheld 8,053 shares at a price of $16.96 to cover mandatory tax withholding requirements.
- Following these transactions, Graf Finckenstein directly owns 41,177 shares of Iovance Biotherapeutics common stock and 31,252 RSUs.
- The remaining RSUs will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This is a routine transaction filing, indicating standard compensation practices. It doesn't inherently suggest positive or negative sentiment.
Future Outlook
The remaining RSUs will vest in equal quarterly installments.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates routine vesting of previously granted equity compensation.
Stakeholder Impact
- The vesting of RSUs and subsequent tax withholding may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/02/2023 | Date of original RSU grant. |
| 03/04/2024 | Date of RSU vesting and tax withholding. |
| 03/06/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.